Monitoring gene changes during antiepileptic drug therapy to widen the safety window and reduce pharmacoresistance

Epilepsia

Volumn 48, Issue SUPPL. 1, 2007, Pages 19-25

  Glauser, Tracy A ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Adverse drug reactions; Adverse events; AED; Antiepileptic drug; Drug toxicity; Gene expression; Genomics; Pharmacoresistance; Refractory epilepsy

Indexed keywords

ANTICONVULSIVE AGENT; BIOLOGICAL MARKER; CARBAMAZEPINE; DNA; FELBAMATE; GABAPENTIN; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; RNA; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

BONE DENSITY; BONE TURNOVER; CONFERENCE PAPER; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FRACTURE; GENE EXPRESSION REGULATION; GENOMICS; GINGIVA OVERGROWTH; HIGH RISK POPULATION; HUMAN; METABOLITE; PRIORITY JOURNAL; SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

ANTICONVULSANTS; DRUG RESISTANCE; EPILEPSY; GENE EXPRESSION; HUMANS; MICROARRAY ANALYSIS; PHARMACOGENETICS; PHENOTYPE; TREATMENT OUTCOME;

EID: 33847121300     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2007.00995.x     Document Type: Conference Paper

References (43)

1. Brodie MJ. Diagnosing and predicting refractory epilepsy. Acta Neurol Scand Suppl 2005;181:36-9.
2. Langman LJ, Kapur BM. Toxicology: then and now. Clin Biochem 2006;39:498-510.
3. Wax PM. Elixirs, diluents, and the passage of the 1938 Federal Food, Drug and Cosmetic Act. Ann Intern Med 1995;122:456-61.
4. Wax PM. Elixir sulfanilamide-Massengill revisited.Vet HumToxicol 1994;36:561-2.
5. Hodel C, Bass R. Are newer scientific concepts in regulatory toxicology used timely and appropriately? Toxicol Lett 1992;64-65 Spec No:149-55.
6. Dogne JM, Hanson J, Supuran C, et al. Coxibs and cardiovascular side-effects: from light to shadow. Curr Pharm Des 2006;12:971-5.
7. Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006;47:1094-120.
8. Park BK, Pirmohamed M, Kitteringham NR. Idiosyncratic drug reactions: a mechanistic evaluation of risk factors. Br J Clin Pharmacol 1992;34:377-95.
9. Pirmohamed M, Kitteringham NR, Park BK. The role of active metabolites in drug toxicity. Drug Saf 1994;11:114-44.
10. Pellock JM. Standard approach to antiepileptic drug treatment in the United States. Epilepsia 1994;35(suppl 4):S11-8.
11. Biton V. Effect of antiepileptic drugs on bodyweight: overview and clinical implications for the treatment of epilepsy. CNS Drugs 2003;17:781-91.
12. Sheth RD. Metabolic concerns associated with antiepileptic medications. Neurology 2004;63(10 suppl 4):S24-9.
13. Mintzer S, Boppana P, Toguri J, et al. Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine. Epilepsia 2006;47:510-5.
14. Casetta I, Granieri E, Desidera M, et al. Phenytoin-induced gingival overgrowth: a community-based cross-sectional study in Ferrara, Italy. Neuroepidemiology 1997;16:296-303.
15. Kalow W. Pharmacogenetics: heredity and the response to drugs. Philadelphia: W. B. Saunders Company, 1962.
16. Nebert DW. Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? Clin Genet 1999;56:247-58.
17. Clancy CE, Kass RS. Pharmacogenomics in the treatment of epilepsy. Pharmacogenomics 2003;4:747-51.
18. Shi MM. Technologies for individual genotyping: detection of genetic polymorphisms in drug targets and disease genes. Am J Pharmacogenomics 2002;2:197-205.
19. Nebert DW, Vesell ES. Advances in pharmacogenomics and individualized drug therapy: exciting challenges that lie ahead. Eur J Pharmacol 2004;500:267-80.
20. Nuwaysir EF, Bittner M, Trent J, et al. Microarrays and toxicology: the advent of toxicogenomics. Mol Carcinog 1999;24:153-9.
21. Brown PO, Botstein D. Exploring the new world of the genome with DNA microarrays. Nat Genet 1999;21(1 suppl):33-7.
22. Staudt LM, Flavell RA. Genomics, genetics, and genes of the immune system. Immunity 2001;15:335-6.
23. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999;286:531-7.
24. Tyers M, Mann M. From genomics to proteomics. Nature 2003;422:193-7.
25. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 2003;422:198-207.
26. Dettmer K, Aronov PA, Hammock BD. Mass spectrometry-based metabolomics. Mass Spectrom Rev 2006.
27. Nebert DW, Jorge-Nebert L, Vesell ES. Pharmacogenomics and "individualized drug therapy": high expectations and disappointing achievements. Am J Pharmacogenomics 2003;3:361-70.
28. Imbeaud S, Auffray C. 'The 39 steps' in gene expression profiling: critical issues and proposed best practices for microarray experiments. Drug Discov Today 2005;10:1175-82.
29. Jallon P, Picard F. Bodyweight gain and anticonvulsants: a comparative review. Drug Saf 2001;24:969-78.
30. Egger J, Brett EM. Effects of sodium valproate in 100 children with special reference to weight. Br Med J (Clin Res Ed) 1981;283:577-81.
31. Novak GP, Maytal J, Alshansky A, et al. Risk of excessive weight gain in epileptic children treated with valproate. J Child Neurol 1999;14:490-5.
32. Easter D, O'Bryan-Tear CG, Verity C. Weight gain with valproate or carbamazepine-a reappraisal. Seizure 1997;6:121-5.
33. Proposal for classification of epilepsies and epileptic syndromes. Commission on classification and terminology of the international league against epilepsy. Epilepsia 1985;26:268-78.
34. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 1981;22:489-501.
35. Proposal for revised classification of epilepsies and epileptic syndromes. From the Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 1989;30:389-99.
36. PreAnalytiX GmbH, PAXgene Blood RNA System. Instructions for use. 2006. (Available at http://www.Preanalytix.com/RNA_Instr.asp)
37. Affymetrix, GeneChip Expression Analysis Technical Manual, 2004. (Available at http://www.affymetrix.com/support/technical/manual/ expression_manual.affx)
38. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-64.
39. Irizarry R, Gautier L, Cope LM. An R package for oligonucleotide array statistical analysis. In: Parmigiani G, Garrett ES, Irizarry RA, et al, eds. The analysis of gene expression data: methods and software. New York: Springer-Verlag; 2003:102-19.
40. Gautier L, Cope L, Bolstad BM, et al. Affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 2004;20:307-15.
41. Field AE, Laird N, Steinberg E, et al. Which metric of relative weight best captures body fatness in children? Obes Res 2003;11:1345-52.
42. Cole TJ, Faith MS, Pietrobelli A, et al. What is the best measure of adiposity change in growing children: BMI, BMI %, BMI z-score or BMI centile? Eur J Clin Nutr 2005;59:419-25.
43. Oltvai ZN, Barabasi AL. Systems biology. Life's complexity pyramid. Science 2002;298:763-4.